Tremeau Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$110M
- Investors
-
1
Tremeau Pharmaceuticals General Information
Description
Developer of non-opioid pain therapies designed to help patients with bleeding concerns. The company's product helps with acute and chronic pain in select conditions, has documented efficacy in painful inflammatory conditions, and has a clinically differentiated profile, enabling patients to receive therapeutic advantages over other standards of care, such as opioids.
Contact Information
Website
www.tremeau.comCorporate Office
- 53 Main Street
- Suite 202
- Concord, MA 01742
- United States
Corporate Office
- 53 Main Street
- Suite 202
- Concord, MA 01742
- United States
Tremeau Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 14-Jan-2019 | $110M | Completed | Clinical Trials - General | ||
| 1. Seed Round | 14-Feb-2018 | Completed | Startup |
Tremeau Pharmaceuticals Comparisons
Industry
Financing
Details
Tremeau Pharmaceuticals Competitors (3)
One of Tremeau Pharmaceuticals’s 3 competitors is Pacira BioSciences, a Formerly VC-backed company based in Tampa, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pacira BioSciences | Formerly VC-backed | Tampa, FL | ||||
| Frenelle Pharma | Venture Capital-Backed | Plymouth, MN | ||||
| Vapogenix | Venture Capital-Backed | Houston, TX |
Tremeau Pharmaceuticals Patents
Tremeau Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023059698-A1 | Methods and compositions for treating von willebrand's migraine disorder | Inactive | 06-Oct-2021 | ||
| WO-2022216975-A8 | Deuterated etoricoxib, methods of manufacture and use thereof | Inactive | 09-Apr-2021 | ||
| CA-3214485-A1 | Deuterated etoricoxib, methods of manufacture, and use thereof | Pending | 09-Apr-2021 | ||
| JP-2023548380-A | Aqueous formulation of water-insoluble cox-2 inhibition | Pending | 28-Oct-2020 | ||
| CA-3200132-A1 | Aqueous formulations of water insoluble cox-2 inhibitors | Pending | 28-Oct-2020 | A61K31/444 |
Tremeau Pharmaceuticals Signals
Tremeau Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| B-FLEXION Life Sciences | PE/Buyout | Minority |
Tremeau Pharmaceuticals FAQs
-
When was Tremeau Pharmaceuticals founded?
Tremeau Pharmaceuticals was founded in 2016.
-
Where is Tremeau Pharmaceuticals headquartered?
Tremeau Pharmaceuticals is headquartered in Concord, MA.
-
What is the size of Tremeau Pharmaceuticals?
Tremeau Pharmaceuticals has 15 total employees.
-
What industry is Tremeau Pharmaceuticals in?
Tremeau Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Tremeau Pharmaceuticals a private or public company?
Tremeau Pharmaceuticals is a Private company.
-
What is Tremeau Pharmaceuticals’s current revenue?
The current revenue for Tremeau Pharmaceuticals is .
-
How much funding has Tremeau Pharmaceuticals raised over time?
Tremeau Pharmaceuticals has raised $115M.
-
Who are Tremeau Pharmaceuticals’s investors?
B-FLEXION Life Sciences has invested in Tremeau Pharmaceuticals.
-
Who are Tremeau Pharmaceuticals’s competitors?
Pacira BioSciences, Frenelle Pharma, and Vapogenix are competitors of Tremeau Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process